Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Prudence and promise in psychedelic-assisted therapy

Charles Saylor and Jacob M. Appel, MD, JD, MPH
Meds
November 30, 2022
34 Shares
Share
Tweet
Share

Psychedelic-assisted therapy (PAT) represents one of the most promising developments in psychiatry in decades. The treatment typically involves the infusion of a compound such as LSD, psilocybin, or MDMA during an extended therapy session with licensed professionals.

Although it lacks widespread regulatory approval or clinical use, significant advances have been made in the study of PAT in the past decade, with a pronounced increase in recent years. Recently, a study published in the New England Journal of Medicine demonstrated that a single 25mg dose of psilocybin (the active compound in psychedelic mushrooms) accompanied by psychotherapy was effective in reducing symptoms in patients with treatment-resistant depression, a condition that is notoriously difficult to treat.

This study is the most recent example in a pattern of trials demonstrating PAT’s efficacy for everything from PTSD to alcohol use disorder. However, the field dates to the mid-20th century, when doctors conducted studies that, despite poor design, used the exact same compounds (e.g., LSD) for very similar psychiatric conditions (e.g., alcohol use disorder). This initial groundswell of research in the 50s and 60s was doomed by political and social forces in the United States that halted funding and led to a decades-long hiatus, of which the field has only recently emerged.

Its resurgence is also steeped in controversy. Valid criticism has been levied against clinical trials which use consciousness-altering medications that are difficult (or impossible) to control for with placebo. In contrast to most large placebo-controlled clinical trials, many trials of PAT have pathetic blinding results, with over 90 percent of participants correctly guessing whether they received active medication or placebo. This muddies the waters of the analysis and makes it difficult to attribute results to the treatment, the placebo, or both. The NEJM study didn’t bother with placebo and instead used lower doses of psilocybin as comparators – patients who got the lower doses had less of a response.

These studies can also be subject to expectancy effects. Just as a jury may be inadvertently swayed by press coverage or social media, patients who are familiar with the tremendous promise or “hype” surrounding PAT may be more likely to believe the treatment works and thus respond positively to the intervention.

There is also a discrepancy between the public understanding of PAT and the actual state of the field. Microdosing, which some claim will boost creativity, and productivity or treat psychiatric conditions, is unrelated to PAT and largely lacks evidence of its validity. Ketamine, which is widely used for psychiatric indications, is another unrelated entity: it is not structurally related to classical psychedelics, nor is it typically administered during therapy sessions.

Also, PAT is a synthesis of both therapy and medication. Dosing typically involves an infusion that is administered during a monitored therapy session, not picked up from a pharmacy. This is in stark contrast to the distribution of other sensitive medications like opioids or Adderall, but many fail to recognize the difference.

Also, there have been very few trials of PAT that adequately reflect the racial or ethnic makeup of the United States. Many groundbreaking studies have recruited mostly white participants, limiting the generalizability of any findings. The NEJM paper was no different — more than 90 percent of the participants were white. The therapy session/infusion is also a prolonged process, which can take many hours, making it difficult for many people to access these treatments. If you cannot reasonably take a day off from work, how could you expect to attend multiple 8-hour treatment sessions?

Finally, PAT has begun to take on the appearance of a silver bullet, which can treat a wide range of conditions that may not have similar pathological mechanisms. This should give pause to many clinicians and regulators; new therapies are often touted as being more effective than they really are. If expectations are inflated beyond reality, it will endanger what may be a valid and effective tool in the arsenal of our country’s psychiatrists.

The United States is in a crisis of mental health care. As psychiatrists, we are keenly aware of the urgent need for novel interventions for conditions ranging from PTSD to cigarette addiction to depression. Many millions of people may be safely and effectively treated by PAT, and regulatory approval or rejection of PAT could be imminent. However, the accelerating excitement surrounding PAT threatens to endanger the cause itself. While recent results have been exciting, and there is plenty of work ahead of us, and the best path forward is a measured, cautious approach that also allows for the safest and most evidence-based therapies to reach the largest number of people.

Charles Saylor is a medical student. Jacob M. Appel is a psychiatrist.

Image credit: Shutterstock.com

Prev

A doctor's grief

November 30, 2022 Kevin 2
…
Next

Effective doctors need to be challenged [PODCAST]

November 30, 2022 Kevin 0
…

Tagged as: Psychiatry

Post navigation

< Previous Post
A doctor's grief
Next Post >
Effective doctors need to be challenged [PODCAST]

Related Posts

  • Stop stigmatizing medication-assisted treatment

    Brandon Jacobi
  • What doctors need to know about psychedelic medicine

    Lynn Marie Morski, MD, JD
  • Hormone replacement therapy is still linked to cancer

    Martha Rosenberg
  • Art therapy and the intersection between chronic illness and mental health

    Amy Oestreicher
  • America’s prescription epidemic: Breaking an ancient promise

    Jesse Seilern und Aspang, MD, Riana Patel, MD and Mara Schenker, MD
  • Medicare for all: a campaign promise, catchy bumper sticker, or viable program?

    Bonnie Friedman

More in Meds

  • The deadly consequences of a shortage: The Pluvicto crisis leaves metastatic prostate cancer patients in limbo

    Matt Drewes
  • The real story of Xylazine contamination in street fentanyl and how we can manage it

    Julie Craig, MD
  • The cannabis education gap: Why patients are left in the dark

    Timothy Byars
  • Are doctors ready to discuss psychedelic therapies with patients?

    Thaís Salles Araujo, MD
  • The rise and dark side of fungi: Exploring health benefits and pathogenic threats

    Sandra Vamos, EdD and Deanna Lernihan, MPH
  • Advocacy and collaboration lead to major patient safety benefits on sterile pharmaceutical compounding: a review of USP’s revisions to Chapter <797>

    Elizabeth Rebello, MD
  • Most Popular

  • Past Week

    • A patient’s perspective on the diminishing relationship between doctors and patients

      Michele Luckenbaugh | Conditions
    • How chronic illness and disability are portrayed in media and the importance of daily choices for improved quality of life

      Juliet Morgan and Meghan Jobson | Physician
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
  • Past 6 Months

    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
  • Recent Posts

    • The pros and cons of taking a gap year during medical school

      Med School Insiders | Education, Sponsored
    • A family physician’s journey on the OIG list and the struggle to return to practice [PODCAST]

      The Podcast by KevinMD | Podcast
    • Heartwarming stories of cancer patients teaching us about life and the human spirit

      Johnathan Yao, MD, MPH | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
    • The meaning of death in medicine: the role of compassionate care in end-of-life patient care

      Ton La, Jr., MD, JD | Physician
    • From skydiving to saving lives: a surgeon’s journey on adversity, passion, and perseverance [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Catching the Optimal Amount of Z's May Be Protective Against Long COVID
  • Treating Early Hospitalization Blood Pressure Deemed a No-No for Patient Safety
  • Addressing Burnout in an Invisible Part of the Health Workforce
  • Family-Oriented Sedation Protocol Helps Kids With ASD Manage Routine Healthcare
  • Bariatric Surgery in Kids With Obesity Becoming More Common

Meeting Coverage

  • New Model Aims to Study Intestinal Fibrosis in Crohn's Disease
  • Hypertension Tied to Worse Survival After Surgery for Upper Tract Urothelial Cancers
  • The Role of Amyloid PET in the Management of Alzheimer's Disease
  • New Inflammation Inhibitor Proves Effective and Safe for Dry Eye Disease
  • No Access to Routine Healthcare Biggest Barrier to HPV Vaccination
  • Most Popular

  • Past Week

    • A patient’s perspective on the diminishing relationship between doctors and patients

      Michele Luckenbaugh | Conditions
    • How chronic illness and disability are portrayed in media and the importance of daily choices for improved quality of life

      Juliet Morgan and Meghan Jobson | Physician
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
  • Past 6 Months

    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
  • Recent Posts

    • The pros and cons of taking a gap year during medical school

      Med School Insiders | Education, Sponsored
    • A family physician’s journey on the OIG list and the struggle to return to practice [PODCAST]

      The Podcast by KevinMD | Podcast
    • Heartwarming stories of cancer patients teaching us about life and the human spirit

      Johnathan Yao, MD, MPH | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
    • The meaning of death in medicine: the role of compassionate care in end-of-life patient care

      Ton La, Jr., MD, JD | Physician
    • From skydiving to saving lives: a surgeon’s journey on adversity, passion, and perseverance [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Prudence and promise in psychedelic-assisted therapy
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...